Physician profile
Michael E Townsend
NPI 1427024504
$2,172.40
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $221 · 2021: $446 · 2022: $454 · 2023: $400 · 2024: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $890.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $553.22 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $227.16 | 2020-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $208.12 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $166.51 | 2021-2024 | |
| Amgen INC. | $124.81 | 2021-2024 | Otezla, Repatha, Prolia |
| Merck Sharp & Dohme LLC | $123.62 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Abbott Laboratories | $119.02 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $106.35 | 2019-2024 | |
| Abbvie INC. | $86.07 | 2021-2022 | |
| Astellas Pharma US INC | $78.64 | 2023-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.62 | 2020-2024 | Xifaxan |
| Amarin Pharma, INC. | $50.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.26 | 2019-2022 | |
| Exact Sciences Corporation | $42.73 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $38.13 | 2020-2024 | Nexletol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $22.21 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Axonics, INC. | $22.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.66 | 2023 | Gvoke Hypopen |
| Biogen, INC. | $18.56 | 2021 | |
| Medtronic, INC. | $16.12 | 2024 | Intellis Adaptivestim |
| Lucid Diagnostics INC. | $16.07 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.52 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.00 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Townsend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.